Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States
Diabetes, Obesity and Metabolism · 2026-04 · 28 (4) · 2661-2671
DOI: 10.1111/dom.70440 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 08.01.2026. Verfasst von Xi Tan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk Inc., Plainsboro, New Jersey, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Immunoglobulin Fc Fragments, Diabetes Mellitus, Type 2, Recombinant Fusion Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide. Materials and methods This was a retrospective cohort study using Optum's de‐identified Clinformatics Data Mart (Optum CDM) from 1 January 2007 through 30 September 2024. New initiators of semaglutide or dulaglutide ≥18 years with both T2D and ASCVD were included. The index date was the first date of a prescription claim for semaglutide or dulaglutide within the index medication identification period (1 January 2018 through 31 March 2024). The primary outcome was 3‐point MACE (stroke, myocardial infarction [MI], cardiovascular [CV]‐related death). Entropy balancing was applied to balance baseline characteristics. Weighted incidence rates per 1000 person‐years and doubly robust Cox proportional hazard ratios were reported.
Results
There were 75 243 enrolees included (semaglutide, 42 007; dulaglutide, 33 236). The mean age was 68.2 and 69.3 years (unweighted) in the semaglutide and dulaglutide cohorts, respectively. After balancing, standardized mean differences were
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novo Nordisk Inc., Plainsboro, New Jersey, USA.
- Genesis Research Group, Hoboken, New Jersey, USA.
- Department of Neurology, Center for Brain and Mind Health, Yale University, New Haven, Connecticut, USA.
ORCID-Profile: Xi Tan
Förderung
- Novo Nordisk
Zitieren
APA
Tan, X., Liang, Y., Xie, L., Harton, J., Gutierrez, C., Muhammad, C., Swift, C., & de Havenon, A. (2026). Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States. Diabetes, Obesity and Metabolism, 28(4), 2661-2671. https://doi.org/10.1111/dom.70440
Vancouver
Tan X, Liang Y, Xie L, Harton J, Gutierrez C, Muhammad C, et al. Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States. Diabetes, Obesity and Metabolism. 2026;28(4):2661-2671. doi:10.1111/dom.70440
BibTeX
@article{Tan2026,
author = {Tan, Xi and Liang, Yuanjie and Xie, Lin and Harton, Joanna and Gutierrez, Cynthia and Muhammad, Chalak and Swift, Caroline and de Havenon, Adam},
title = {Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {4},
pages = {2661--2671},
doi = {10.1111/dom.70440}
}
EUVIMED